Epicardial and Perihepatic Fat as Cardiometabolic Risk Predictors in Girls with Turner Syndrome: A Cardiac Magnetic Resonance Study
PDF

Original Article

Epicardial and Perihepatic Fat as Cardiometabolic Risk Predictors in Girls with Turner Syndrome: A Cardiac Magnetic Resonance Study

J Clin Res Pediatr Endocrinol 2021;13(4):408-417 DOI: 10.4274/jcrpe.galenos.2021.2021.0030
, , , , , ,
PDF
Permissions

Abstract

Objective:

Turner syndrome (TS) patients are at high risk of cardiometabolic disorders. Cardiometabolic risk factors are more commonly related to visceral rather than total body adiposity. Adipocytokines have been explored as a potential link between obesity and obesity-related cardiometabolic dysfunction. This study explored the validity of epicardial fat-thickness (EFT) and perihepatic fat-thickness (PHFT) measurement as cardiometabolic-risk predictors in TS-girls in relation to standard obesity-indices and metabolic syndrome (MetS) components.

Methods:

Forty-six TS girls and twenty-five controls (10-16 years) were subdivided into two age-groups (10 to less than 13 and 13-16). Participants were assessed for body mass index (BMI) Z-scores, waist circumference (WC), total-fat mass (FM) and trunk-FM by bioimpedance-technique, EFT and PHFT by cardiovascular magnetic resonance, lipid-profile, homeostasis model assessment of insulin resistance (HOMA-IR), and serum chemerin. MetS was defined according to International Diabetes Federation criteria.

Results:

Overweight/obesity and MetS were detected in 45.7% and 37% of TS-girls respectively. BMI Z-score, WC, total-FM, trunk-FM, EFT and PHFT values were significantly higher in TS-age groups compared to age-matched control groups, being more pronounced in the older group when TS-girls had been exposed to estrogen. Dyslipidemia, higher HOMA-IR, chemerin, EFT and PHFT values were observed in lean-Turner compared to BMI-Z-matched controls. EFT and PHFT were significantly correlated with chemerin and several components of MetS. EFT at a cut-off-value of 6.20 mm (area under the curve=0.814) can predict MetS in TS-girls.

Conclusion:

TS-girls displayed an adverse cardiometabolic profile during late childhood and adolescence. EFT and PHFT are emerging cardiometabolic risk predictors in TS-patients. Excess EFT rather than total body adiposity may contribute to altered metabolic profile among lean-Turner patients.

Keywords: Epicardial fat, perihepatic fat, metabolic syndrome, Turner syndrome

Read the full text

6 sections · PDF

Create your free account to read the full text.

  • Full text with figures and tables
  • PDF and supplementary files
  • Access on every Galenos journal
Get free access

Already have an account?

Sign in
or
Continue with Google

One Galenos account works on every Galenos journal site.

References

1

Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics. 2018;141:e20173459. Erratum in: Pediatrics 2018;142:e20181916. 2018 Feb 26.

2

Magge SN, Goodman E, Armstrong SC; Committee on Nutrition; Section on Endocrinology; Section on Obesity. The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering. Pediatrics 2017;140:e20171603.

3

Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, de Vries L, Tenenbaum A, Phillip M, Lazar L; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 2017;177:G1-G70.

4

Gawlik A, Gieburowska J, Malecka-Tendera E. Czynniki ryzyka sercowo-metabolicznego w zespole Turnera [Cardiometabolic risk factors in Turner syndrome]. Pediatr Endocrinol Diabetes Metab 2015;20:69-74.

5

O’Gorman CS, Syme C, Lang J, Bradley TJ, Wells GD, Hamilton JK. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome. Clin Endocrinol (Oxf) 2013;78:907-913. Epub 2013 Apr 6

6

Mazzanti L, Bergamaschi R, Castiglioni L, Zappulla F, Pirazzoli P, Cicognani A. Turner syndrome, insulin sensitivity and growth hormone treatment. Horm Res 2005;64(Suppl 3):51-57. Epub 2006 Jan 20

7

Lebenthal Y, Levy S, Sofrin-Drucker E, Nagelberg N, Weintrob N, Shalitin S, de Vries L, Tenenbaum A, Phillip M, Lazar L. The natural history of metabolic comorbidities in turner syndrome from childhood to early adulthood: comparison between 45,x monosomy and other karyotypes. Front Endocrinol (Lausanne) 2018;9:27.

8

Gray SL, Vidal-Puig AJ. Adipose tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 2007;65:S7-S12.

9

Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7:715-725. Epub 2019 Jul 10

10

Bertaso AG, Bertol D, Duncan BB, Foppa M. Epicardial fat: definition, measurements and systematic review of main outcomes. Arq Bras Cardiol 2013;101:e18-e28.

11

Nagy E, Jermendy AL, Merkely B, Maurovich-Horvat P. Clinical importance of epicardial adipose tissue. Arch Med Sci 2017;13:864-874. Epub 2016 Oct 26

12

Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc 2014;3:e000582.

13

Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009;22:1311-1319; quiz 1417-1418.

14

Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-28188. Epub 2007 Jul 16

15

Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009;161:339-344. Epub 2009 Jun 4

16

Wu Q, Chen Y, Chen S, Wu X, Nong W. Correlation between adiponectin, chemerin, vascular endothelial growth factor and epicardial fat volume in patients with coronary artery disease. Exp Ther Med 2020;19:1095-1102. Epub 2019 Dec 5

17

Kaur J, Mattu HS, Chatha K, Randeva HS. Chemerin in human cardiovascular disease. Vascul Pharmacol 2018;110:1-6. Epub 2018 Aug 3

18

Ghalli I, Salah N, Hussien F, Erfan M, El-Ruby M, Mazen I, et al. Egyptian growth curves for infants, children and adolescents 2002. In: Satorio A, Buckler JMH, Marazzi N (eds). Italy: Ferring Publisher; 2008.

19

Bonthuis M, Jager KJ, Abu-Hanna A, Verrina E, Schaefer F, van Stralen KJ. Application of body mass index according to height-age in short and tall children. PLoS One 2013;8:e72068.

20

de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660-667.

21

Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140:e20171904. Erratum in: Pediatrics 2017. Erratum in: Pediatrics 2018;142. Epub 2017 Aug 21

22

Calcaterra V, Brambilla P, Maffè GC, Klersy C, Albertini R, Introzzi F, Bozzola E, Bozzola M, Larizza D. Metabolic syndrome in Turner syndrome and relation between body composition and clinical, genetic, and ultrasonographic characteristics. Metab Syndr Relat Disord 2014;12:159-164. Epub 2014 Jan 21

23

Álvarez-Nava F, Racines M, Witt J, Guarderas J, Estévez M, Lanes R. Anthropometric variables as cardiovascular risk predictors in a cohort of adult subjects with Turner syndrome. Diabetes Metab Syndr Obes 2019;12:1795‐1809.

24

Kim SJ, Kim HS, Jung JW, Kim NS, Noh CI, Hong YM. Correlation between epicardial fat thickness by echocardiography and other parameters in obese adolescents. Korean Circ J 2012;42:471-478. Epub 2012 Jul 26.

25

Akyol B, Boyraz M, Aysoy C. Relationship of epicardial adipose tissue thickness with early indicators of atherosclerosis and cardiac functional changes in obese adolescents with metabolic syndrome. J Clin Res Pediatr Endocrinol 2013;5:156-163.

26

López-Bermejo A, Prats-Puig A, Osiniri I, Martínez-Calcerrada JM, Bassols J. Perirenal and epicardial fat and their association with carotid intima-media thickness in children. Ann Pediatr Endocrinol Metab 2019;24:220-225. Epub 2019 Dec 31

27

Ostberg JE, Thomas EL, Hamilton G, Attar MJ, Bell JD, Conway GS. Excess visceral and hepatic adipose tissue in Turner syndrome determined by magnetic resonance imaging: estrogen deficiency associated with hepatic adipose content. J Clin Endocrinol Metab 2005;90:2631-2635. Epub 2005 Feb 15.

28

Abaci A, Tascilar ME, Saritas T, Yozgat Y, Yesilkaya E, Kilic A, Okutan V, Lenk MK. Threshold value of subepicardial adipose tissue to detect insulin resistance in obese children. Int J Obes (Lond) 2009;33:440-446. Epub 2009 Feb 17

29

Okyay K, Balcioglu AS, Tavil Y, Attar MJ, Bell JD, Conway GS. A relationship between echocardiographic subepicardial adipose tissue and metabolic syndrome. Int J Cardiovasc Imaging 2008;24:577-583. Epub 2008 Jan 26.

30

Thomas EL, Frost G, Taylor-Robinson SD, Bell JD. Excess body fat in obese and normal-weight subjects. Nutr Res Rev 2012;25:150-161.

31

Zhang Y, Chen RM, Lin XQ, Yuan X, Yang XH. The correlation between serum adipokines levels and metabolic indicators in girls with Turner syndrome. Cytokine 2019;113:139-143.